California State Teachers Retirement System Acquires 14,987 Shares of AtriCure, Inc. $ATRC

California State Teachers Retirement System grew its holdings in AtriCure, Inc. (NASDAQ:ATRC) by 33.3% in the 1st quarter, HoldingsChannel reports. The institutional investor owned 59,947 shares of the medical device company’s stock after acquiring an additional 14,987 shares during the period. California State Teachers Retirement System’s holdings in AtriCure were worth $1,710,000 at the end of the most recent quarter.

Several other hedge funds have also recently made changes to their positions in ATRC. Quantinno Capital Management LP bought a new position in shares of AtriCure during the first quarter valued at approximately $277,000. Lazard Asset Management LLC boosted its holdings in AtriCure by 8.6% in the first quarter. Lazard Asset Management LLC now owns 54,015 shares of the medical device company’s stock valued at $1,541,000 after acquiring an additional 4,296 shares in the last quarter. Rice Hall James & Associates LLC bought a new stake in AtriCure in the first quarter valued at $719,000. Entropy Technologies LP increased its position in AtriCure by 26.5% during the 1st quarter. Entropy Technologies LP now owns 11,493 shares of the medical device company’s stock valued at $328,000 after purchasing an additional 2,408 shares during the period. Finally, Arrowstreet Capital Limited Partnership purchased a new position in AtriCure during the 1st quarter valued at $7,922,000. 99.11% of the stock is owned by hedge funds and other institutional investors.

AtriCure Trading Up 1.4%

NASDAQ:ATRC opened at $43.56 on Thursday. The firm has a market capitalization of $2.22 billion, a P/E ratio of 207.44 and a beta of 1.20. The company has a debt-to-equity ratio of 0.14, a current ratio of 4.22 and a quick ratio of 3.19. AtriCure, Inc. has a one year low of $25.36 and a one year high of $43.84. The company’s 50-day simple moving average is $33.24 and its 200 day simple moving average is $31.40.

AtriCure (NASDAQ:ATRC) last announced its earnings results on Thursday, July 23rd. The medical device company reported $0.18 earnings per share for the quarter. AtriCure had a net margin of 1.85% and a return on equity of 2.34%. The business had revenue of $153.60 million during the quarter, compared to the consensus estimate of $151.80 million. During the same quarter last year, the firm earned ($0.13) earnings per share. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. As a group, analysts forecast that AtriCure, Inc. will post 0.2 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have commented on the stock. UBS Group decreased their price objective on shares of AtriCure from $55.00 to $50.00 and set a “buy” rating for the company in a report on Tuesday, July 28th. Zacks Research raised shares of AtriCure from a “hold” rating to a “strong-buy” rating in a research note on Friday, July 24th. Canaccord Genuity Group boosted their price target on shares of AtriCure from $53.00 to $55.00 and gave the company a “buy” rating in a research report on Wednesday, May 6th. Weiss Ratings raised shares of AtriCure from a “sell (e+)” rating to a “sell (d+)” rating in a research note on Tuesday, July 28th. Finally, Wall Street Zen downgraded shares of AtriCure from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 2nd. Two investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, AtriCure presently has a consensus rating of “Moderate Buy” and a consensus price target of $48.50.

Insider Buying and Selling

In other AtriCure news, Director Sven Wehrwein sold 25,000 shares of AtriCure stock in a transaction on Tuesday, July 28th. The stock was sold at an average price of $37.84, for a total transaction of $946,000.00. Following the completion of the transaction, the director owned 40,518 shares in the company, valued at approximately $1,533,201.12. The trade was a 38.16% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Karen Prange sold 3,564 shares of the business’s stock in a transaction on Wednesday, August 5th. The stock was sold at an average price of $38.80, for a total value of $138,283.20. Following the completion of the sale, the director directly owned 22,809 shares in the company, valued at $884,989.20. This trade represents a 13.51% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 47,246 shares of company stock worth $1,777,845 over the last three months. Corporate insiders own 4.00% of the company’s stock.

AtriCure Profile

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.